Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related kaposi sarcoma in Zimbabwe

Clinical Infectious Diseases

Volumn 51, Issue 3, 2010, Pages 342-349

  Borok, Margaret ^a   Fiorillo, Suzanne ^b   Gudza, Ivy ^a   Putnam, Beverly ^b   Ndemera, Buxton ^a   White, Irene E ^b   Gwanzura, Lovemore ^a   Schooley, Robert T ^c   Campbell, Thomas B ^b  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; BLEOMYCIN; COTRIMOXAZOLE; DOXORUBICIN; ETOPOSIDE; LAMIVUDINE; NEVIRAPINE; VINCRISTINE; VIRUS DNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL ARTHRITIS; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CRYPTOCOCCAL MENINGITIS; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HEPATITIS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPOSI SARCOMA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALARIA; MALE; MORTALITY; NEUTROPENIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PNEUMOCYSTIS JIROVECI; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SOFT TISSUE INFECTION; STEVENS JOHNSON SYNDROME; STOMATITIS; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; URINARY TRACT INFECTION; ZIMBABWE; ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD; COMPLICATION; DRUG MONITORING; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; ISOLATION AND PURIFICATION; MIDDLE AGED; PLASMA; PROCEDURES; SARCOMA, KAPOSI; VIROLOGY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG MONITORING; FEMALE; HERPESVIRUS 8, HUMAN; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMA; PROSPECTIVE STUDIES; SARCOMA, KAPOSI; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; ZIMBABWE;

EID: 77954708861     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/654800     Document Type: Article

References (24)

1. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDSrelated cancers in Africa: maturation of the epidemic in Uganda. AIDS 1999; 13:2563-2570.
2. Chokunonga E, Levy LM, Bassett MT, Mauchaza BG, Thomas DB, Parkin DM. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995. Int J Cancer 2000; 85:54-59.
3. Campbell TB, Borok M, Ndemera B, et al. Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe. Clin Infect Dis 2009; 48:1601-1608.
4. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345:84-86.
5. Harrington W, Jr., Sieczkowski L, Sosa C, et al. Activation of HHV-8 by HIV-1 tat. Lancet 1997; 349:774-775.
6. Varthakavi V, Browning PJ, Spearman P. Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus. J Virol 1999; 73:10329-10338.
7. Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology 2000; 266:17-25.
8. Engels EA, Pfeiffer RM, Goedert JJ, et al. HIV/AIDS Cancer Match Study: trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
9. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109-2116.
10. Campbell TB, Borok M, White IE, et al. Relationship of Kaposi's sar coma (KS)-associated Herpesvirus viremia and KS disease in Zimbabwe. Clin Infect Dis 2003; 36:1144-1151.
11. Boffi El Amari, Toutous-Trellu L, Gayet-Ageron A, et al; the Swiss HIV Cohort Study. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral era. AIDS 2008; 22:1019-1028.
12. Division of AIDS. Table for grading severity of adult and pediatric adverse events. 2009. http://rcc.tech-res.com/Document/safetyand pharmacovigilance/DAIDS-AE-GradingTable-Clarification-August 2009-Final.pdf. Accessed 15 June 2010.
13. Krigel RL, Laubenstein LJ, Muggia FM. Kaposi's sarcoma: a new staging classification. Cancer Treatment Reports 1983; 67:531-534.
14. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085-3092.
15. White IE, Campbell TB. Quantitation of cell-free and cell-associated Kaposi's sarcoma-associated herpesvirus DNA by real-time PCR. J Clin Microbiol 2000; 38:1992-1995.
16. Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005; 113:632-639.
17. Martin-Carbonero L, Barrios A, Saballs P, et al; the Caelyx/KS Spanish Study Group. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004; 18:1737-1740.
18. Lichterfeld M, Qurishi N, Hoffmann C, et al; German Clinical AIDS Working Group. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection 2004; 33:140-147.
19. Cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W. A randomized double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 2007; 12:114-123.
20. Nguyen HQ, Magaret AS, Kitahat MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 2008; 22:937-945.
21. Martin-Carbonero L, Palacios R, Valencia E, et al; Caelyx/Kaposi's Sarcoma Spanish Group. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008; 47:410-417.
22. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART era-the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals. J Clin Oncol 2003; 21:2876-2882.
23. Bihl F, Mosam A, Henry LN, et al. Kaposi's sarcoma-associated herpesvirus- specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 2007; 21:1245-1252.
24. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viremia. AIDS 2004; 18:485-493.